ANVS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

ANVS ▼ -29.96% at T+20d

NEUTRAL call ✗ call lost -29.96% · α vs SPY -37.58% · entry $2.67 → $1.87

Next anchor: T+60d in 4h

Last close $1.78 (close Jun 12) · -33.33% from $2.67 entry

Entry anchored
Mar 18, 03:59 PM ET
via Databento tick

T+1d

-2.62%

call -2.62% · α -0.88%

$2.60

settled 3mo ago

T+5d

-19.48%

call -19.48% · α -17.26%

$2.15

settled 3mo ago

T+20d

-29.96%

call -29.96% · α -37.58%

$1.87

settled 8w ago

T+60d

—

call — · α —

—

in 4h

Price Chart

Loading chart...

Executive Summary

Annovis Bio has partnered with NeuroRPM to integrate an FDA-cleared AI-powered digital biomarker platform into its ongoing open-label Parkinson’s disease trial (ANVS-25002). The technology enables real-time, passive monitoring of core PD symptoms using wearables, complementing biological biomarker data from skin-based alpha-synuclein testing to enhance trial precision and real-world evidence collection.

Actionable Insight

Monitor for future data readouts from the ANVS-25002 trial, as enhanced digital biomarker data could strengthen clinical endpoints and support regulatory strategy. No immediate financial impact expected.

Key Facts

Annovis Bio partnered with NeuroRPM to use its FDA-cleared AI platform for real-time monitoring of Parkinson’s symptoms (bradykinesia, tremor, dyskinesia) in the ANVS-25002 open-label study.
The study is enrolling 500 patients; 90 have been enrolled so far.
NeuroRPM’s platform uses wearable sensors for passive, continuous data collection in real-world settings.
Annovis is also using a biomarker test for misfolded phosphorylated alpha-synuclein with >90% sensitivity and specificity.
Data from both digital and biological biomarkers will be used to assess symptom changes and potential disease modification.

Financial Impact

No financial terms disclosed; likely low-cost operational enhancement

R&D efficiencytrial data quality

Risk Factors

Integration challenges with new digital platform may affect data consistency.
No guarantee that improved monitoring will translate into positive clinical outcomes or regulatory approval.

Market Snapshot

Exchange

NYSE

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3258883

7 reports for ANVS

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+5▲ +11.63%May 20, 2026

Filters

Reports for ANVS — sortable, filterable
	Type				Now
May 20, 2026 25d ago	424B5 BEARISH ★ 6/10	$2.15 $1.90	▲ +11.63%	▲ +13.23%	$1.78 (+17.21%)
May 19, 2026 26d ago	424B5 BEARISH ★ 7/10	$2.04 $2.01	▲ +1.47%	▲ +2.71%	$1.78 (+12.75%)
May 15, 2026 4w ago	8-K MIXED ★ 5/10	$2.05 $2.06	▲ +0.49%	▼ −1.13%	$1.78 (−13.17%)
May 15, 2026 4w ago	Press Release BEARISH ★ 6/10	$2.06 $2.23	▼ −8.25%	▼ −7.29%	$1.78 (+13.59%)
Apr 10, 2026 9w ago	Press Release MIXED ★ 6/10	$1.59 $1.87	▲ +17.61%	▲ +13.11%	$1.78 (+11.95%)
Mar 19, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$2.67 $2.15	▼ −19.48%	▼ −17.26%	$1.78 (−33.33%)
Mar 16, 2026 12w ago	Press Release MIXED ★ 6/10	$2.83 $2.50	▼ −11.66%	▼ −9.62%	$1.78 (−37.10%)

US Market Status

Market Closed — Opens in 5h 11m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access